Ixekizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Generalized Pustular Psoriasis
Conditions
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
Trial Timeline
Jul 5, 2019 → Jul 22, 2020
NCT ID
NCT03942042About Ixekizumab
Ixekizumab is a approved stage product being developed by Eli Lilly for Generalized Pustular Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT03942042. Target conditions include Generalized Pustular Psoriasis, Erythrodermic Psoriasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05855967 | Approved | Completed |
| NCT04259346 | Phase 1 | Completed |
| NCT03942042 | Approved | Completed |
| NCT03848416 | Phase 1 | Completed |
| NCT03848403 | Phase 1 | Terminated |
| NCT03485976 | Phase 2 | Completed |
| NCT03099538 | Phase 2 | Completed |
| NCT03137160 | Phase 2 | Completed |
| NCT03073213 | Phase 1 | Completed |
| NCT02387801 | Phase 3 | Completed |
Competing Products
20 competing products in Generalized Pustular Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |
| Escitalopram | AbbVie | Approved | 85 |
| Adalimumab | AbbVie | Phase 3 | 77 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 77 |